FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION	OMB APPROVAL
	Washington, D.C. 20549   INITIAL STATEMENT OF BENEFICIAL	OMB Number                  3235-0104 Expires:              January 31, 2005 Estimated average burden hours per response                      0.5
(Print or Type Responses)	OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility
Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1.    Name and Address of Reporting Person*   Curran, Jr.                                Thomas                        R.                                                (Last)                                        (First)                                   (Middle)	4.    Issuer Name and Ticker or Trading Symbol   Interleukin Genetics, Inc. (ILGN)
c/o Interleukin Genetics, Inc. 135 Beaver Street                                                           (Street)	5.    Relationship of Reporting Person(s) to Issuer                                     (Check all applicable)     X           Director                                           10% Owner                   Officer (give title                              Other (specify below)                            below)
Waltham                    MA                       02452         (City)                                        (State)                                   (Zip)	6.    If Amendment, Date of Original (Month/Day/Year)
2.   Date of Event Requiring Statement (Month/Day/Year)   March 24, 2003	7.    Individual or Joint/Group Filing (Check Applicable Line)            X         Form Filed by One Reporting Person                        Form Filed by More than One Reporting Person
3.    I.R.S. Identification Number of Reporting Person, if an entity (voluntary)

Table I -- Non-Derivative Securities Beneficially Owned
1. Title of Security     (Instr. 4)	2. Amount of Securities     Beneficially Owned      (Instr. 4)	3. Ownership     Form: Direct      (D) or Indirect      (I)    (Instr. 5)	4. Nature of Indirect Beneficial     Ownership     (Instr. 4)
No securities owned

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

Persons who respond to the collection of Information contained in this form are not required
to respond unless the form displays a currently valid OMB control number. (Over)
SEC 1473 (7-02)

Form 3 (continued) Table II -- Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security     (Instr. 4)	2. Date Exer-     cisable and     Expiration     Date     (Month/Day/Year)		3. Title and Amount of Securities     Underlying Derivative Security     (Instr. 4)		4. Conver-      sion or      Exercise      Price of      Deri-      vative      Security	5. Owner-      ship      Form of      Deriv-      ative      Security:      Direct      (D) or      Indirect (I)      (Instr. 5)	6. Nature of Indirect     Beneficial Ownership     (Instr. 5)
	Date Exer- cisable	Expira- tion Date	Title	Amount or Number of Shares
No Securities Owned

Explanation of Responses:

	By /s/ Thoms R. Curran, Jr.	March 25, 2003
**Intentional misstatements or omissions of facts constitute Federal Criminal	**Signature of Reporting Person	Date
Violations      See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed.
          If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB Number.